Phibro Animal Health Corporation

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in developing, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, copper, manganese, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for use in personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 1946 and is headquartered in Teaneck, New Jersey.

PAHC▲

Phibro Animal declares $0.12 quarterly dividend

Phibro Animal declared a quarterly dividend of $0.12 per share. The forward yield is 1.32%. The dividend is payable on September 23 to shareholders of record on September 2, with the ex-dividend date also on September 2.

PAHC ▲

Seeking Alpha·29dRead more ▾

Biotech & Genomic Medicine▲

Branded pharma Q1 results mixed as Eli Lilly leads and Zoetis lags

Branded pharmaceutical stocks posted mixed first-quarter results, with aggregate revenues beating analyst consensus estimates by 3.6%. Merck reported revenues of $16.29 billion, up 4.9% year on year and exceeding expectations by 3%, while Eli Lilly delivered the strongest performance with revenues of $19.8 billion, a 55.5% increase that beat estimates by 13.7%. Zoetis was the weakest, with revenues of $2.26 billion rising just 2.9% and missing expectations by 2.1%. Phibro Animal Health reported revenues of $383.5 million, up 10.3% and beating estimates by 8%, and Bristol-Myers Squibb posted revenues of $11.49 billion, up 2.5% and topping expectations by 7.4%. Share prices across the group have been resilient, rising an average of 6.4% since the latest earnings results.

LLY ▲ZTS ▼BMY ▲MRK ▲PAHC ▲

Biotech & Genomic Medicine ▲

Yahoo Finance·36dRead more ▾

PAHC▼

StockStory picks Cigna and Astrana Health as long-term buys, flags Phibro Animal Health as a sell

StockStory recommends Cigna and Astrana Health for long-term investors while advising against Phibro Animal Health. Cigna is highlighted for its 16.1% annual revenue growth over two years, $277.7 billion in revenue, and 10.9% annual EPS growth over five years. Astrana Health is noted for 55.7% annual revenue growth over two years and 13.2% annual EPS growth over five years. Phibro Animal Health is flagged for its modest $1.5 billion revenue base, projected 2.2% sales growth, and a weak 0.8% free cash flow margin over five years.

ASTH ▲CI ▲PAHC ▼

StockStory·57dRead more ▾